It’s important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.
Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.
Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.
Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.
Advancing next-generation ADCs through payload-focused design, integrated expertise, and collaborative innovation to deliver safer, more selective therapies.
Driving biologics innovation through integrated design, structural biology, and multidisciplinary expertise to accelerate next-generation therapies from concept to clinic.
Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.
Accelerating oncology drug discovery through integrated expertise, innovative modalities, and translational insight to deliver candidates with real clinical impact.
Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.
Advancing CNS drug discovery through integrated models, translational biomarkers, and multidisciplinary expertise to overcome complexity and accelerate therapeutic innovation.
Designing and advancing differentiated small-molecule therapies for obesity and diabetes through integrated expertise, mechanistic insight, and translational strategies.
Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesised and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.
It’s important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.
Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.
Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.
Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.
Advancing next-generation ADCs through payload-focused design, integrated expertise, and collaborative innovation to deliver safer, more selective therapies.
Driving biologics innovation through integrated design, structural biology, and multidisciplinary expertise to accelerate next-generation therapies from concept to clinic.
Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.
Accelerating oncology drug discovery through integrated expertise, innovative modalities, and translational insight to deliver candidates with real clinical impact.
Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.
Advancing CNS drug discovery through integrated models, translational biomarkers, and multidisciplinary expertise to overcome complexity and accelerate therapeutic innovation.
Designing and advancing differentiated small-molecule therapies for obesity and diabetes through integrated expertise, mechanistic insight, and translational strategies.
Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesised and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.
Our team have one thing in common, a passion for protein science. We don’t just deliver high-quality proteins and structural insights; we take time to understand your target and the ultimate aims of the project and tailor our approach accordingly.
With a global team of over 65 protein scientists, Sygnature Discovery provides fully characterized proteins for a wide range of applications including enzymatic assays, in vivo studies, diagnostics, biotherapeutics, crystallography, and cryo-EM.
Whether it’s a single sample for intact mass spectrometry or a full gene-to-structure cryo-EM campaign, every project receives the same level of dedication and enthusiasm.
Soluble and membrane proteins are produced to meet specific goals. Sygnature is one of the few CROs offering all three major structural biology techniques in-house: X-ray crystallography, NMR spectroscopy, and cryo-EM, delivering structures of both novel and known proteins. Scientific excellence and long-term partnership are at the heart of every engagement.
Each project is approached holistically. By understanding the protein target, downstream application, and project objectives, tailored constructs and strategies are designed to maximize success.
Our Protein Science & Structural Biology Solutions
Producing high quality protein that is fit for purpose is often the key to a project’s success. We thrive on challenge, our team has tackled difficult, complex targets including membrane proteins, intrinsically disordered proteins, refolding from inclusion bodies, large complexes, labeled proteins for NMR, and RNA structures solved by crystallography.
Protein Expression & Purification
We design, express, and purify customized soluble and membrane proteins to support your research. Our approach is innovative, interactive, and flexible, built around your needs and powered by our expertise.
We rigorously characterize and quality-control every protein we produce. We also offer standalone services including intact protein mass spectrometry, peptide mapping, SEC-MALS, Fida, dynamic light scattering, thermal stability assays, and NMR.
Providing X-ray crystallography, cryo-EM and NMR, our service isn’t just a final set of co-ordinates, but a detailed analysis of the 3D structure along with our learning and conclusions, driving ideas for project progression and drug design.
Partnering with Sygnature Discovery gives you access to flexible collaboration models, and integrated capabilities that accelerate innovation, strengthen decisions, and drive candidate-quality outcomes.
Expert team
By partnering with us, you gain access to one of the largest Protein Science and Structural Biology teams in the field. We apply our collective knowledge and experience to every challenge.
Clear communication
You’ll have a dedicated scientific lead as your main point of contact ensuring clear communication on timelines, logistics, data, and delivery throughout the project.
Milestone-based approach
We let the data guide the science. Clear decision points give you full control and transparency at every stage.
Specialized teams
Our dedicated cell science team enables efficient protein expression across multiple projects. We also have a specialist membrane protein team focused on solving the most difficult targets.
Collaborative partnership
We work as an extension of your team. Many clients value our scientific engagement and collaborative spirit, and we thrive in that environment.
Flexible cost models
We offer flexible contract models to suit your needs, including standalone fee-for-service and full-time equivalent support.
Meet Our Protein & Structure Directors
Get to know the team powering our protein science and structural biology solutions. From structural insights to bespoke protein design, they bring clarity and confidence to your discovery journey.
![Sygnature TL1A [C95S/C135S] Structure](data:image/svg+xml;base64,PHN2ZyB3aWR0aD0iNDAwIiBoZWlnaHQ9IjM1OSIgeG1sbnM9Imh0dHA6Ly93d3cudzMub3JnLzIwMDAvc3ZnIj48cmVjdCB3aWR0aD0iMTAwJSIgaGVpZ2h0PSIxMDAlIiBmaWxsPSIjZjNmNGY2Ii8+PC9zdmc+)
![Sygnature TL1A [C95S/C135S] Structure](https://www.sygnaturediscovery.com/wp-content/uploads/2025/12/Sygnature-TL1A-Structure-400x359-1.webp)
